In conclusion, activating CDH13 suppressed the NF-κB signaling pathway that induced cells to apoptosis, making BCR-ABL1 independent CML cells more susceptible to imatinib. This evidence concerns the gene CDH13 and chronic myelogenous leukemia, BCR-ABL1 positive.